GHK-Cu is a naturally occurring copper peptide studied across a wide range of biological systems including tissue repair, collagen synthesis, anti-ageing and wound healing pathways. Here is what the research says.
This article is for general educational purposes only and does not constitute medical advice. GHK-Cu is a prescription-only medicine in Australia when used in therapeutic contexts. Access requires assessment and prescription from an AHPRA-registered medical practitioner. Always consult a qualified doctor before making any decisions about your health.
A naturally occurring tripeptide that binds to copper. Found in human plasma, saliva and urine. Levels decline with age.
Studied across tissue repair, collagen synthesis, wound healing, skin biology, inflammation modulation and gene expression research.
Schedule 4 prescription-only medicine in Australia when used therapeutically. Requires a valid prescription from an AHPRA-registered doctor.
GHK-Cu stands for glycyl-L-histidyl-L-lysine copper, which describes both the peptide component and the copper ion it binds to. The peptide itself, GHK, is a naturally occurring tripeptide found in human plasma, saliva and urine. It was first identified in human plasma in the early 1970s and has since been studied across a wide range of biological contexts.
The copper component is significant. Copper is an essential trace mineral involved in numerous biological processes, including collagen synthesis, wound healing, and antioxidant defence. GHK has a strong natural affinity for copper ions, and the GHK-Cu complex is the biologically active form studied in the majority of research.
One of the notable features of GHK-Cu from a research perspective is that plasma concentrations of GHK decline with age, dropping from approximately 200 nanomoles per litre in young adults to significantly lower levels in older populations. This decline has been associated with reduced tissue repair capacity and has contributed to research interest in GHK-Cu in longevity and anti-ageing contexts.
The earliest and most established area of GHK-Cu research relates to tissue repair and wound healing. Studies have examined its interaction with fibroblast activity, the cells responsible for producing collagen and other components of the extracellular matrix. Research has investigated how GHK-Cu influences the rate and quality of tissue repair in various models, including skin, nerve tissue, and bone.
GHK-Cu has been studied extensively in the context of skin biology, particularly its interaction with collagen synthesis pathways. Collagen is the primary structural protein of the skin and its production declines with age. Research has examined whether GHK-Cu can influence collagen production and skin structure. It appears in some topical cosmetic formulations for this reason, though therapeutic applications require proper medical oversight.
More recent research into GHK-Cu has examined its potential influence on gene expression, with studies suggesting it may interact with a broad range of genes involved in inflammation, tissue repair, and cellular maintenance pathways. This area of research is at an earlier stage but has generated significant interest.
Research has also examined GHK-Cu's interaction with inflammatory signalling. Studies in various models have investigated whether it can modulate inflammatory processes, which connects with its broader role in tissue repair given the close relationship between inflammation and healing.
GHK-Cu in cosmetics vs therapeutic use: GHK-Cu appears in some over-the-counter cosmetic products, particularly topical skincare formulations. Therapeutic use involves higher concentrations, specific delivery methods, and medical oversight. When accessed through a compounding pharmacy via prescription, the compound, concentration, and delivery method are determined by a prescribing doctor rather than based on cosmetic product labelling.
The observation that GHK plasma concentrations decline significantly with age has been one of the drivers of research interest in this compound in longevity contexts. The decline coincides broadly with the reduced tissue repair capacity and increased inflammatory baseline that are characteristic of ageing biology. Whether supplementing GHK-Cu can meaningfully influence these processes in humans is an active area of research interest, though the human clinical evidence is less developed than the preclinical evidence at this stage.
In therapeutic contexts, GHK-Cu is treated as a prescription-only medicine in Australia. When prescribed by an AHPRA-registered medical practitioner following a clinical assessment and dispensed through a licensed compounding pharmacy, it is legal to access. The appropriate concentration, form and delivery method are determined by the prescribing doctor based on the individual's circumstances.